Table of Contents
Rising Incidence of Disease Urges Strong Pipeline Development
•An aging population contributes to the demand for Parkinson’s disease therapeutics. The available levodopa-based drugs are modestly effective.
•The drugs available or in the pipeline for Parkinson’s are only used to suppress the symptoms as there is still no cure for the disease.
•Genetic targets, namely ’LRRK2’ and ’alpha-synuclein’, offers a promising future cure for the disease.
•Low, unmet therapeutic response to overall Parkinson’s disease therapeutics corresponds to a smaller pipeline investment in comparison to Alzheimer’s disease and other central nervous system (CNS) disorders.
•Market demand for Parkinson’s disease therapeutics is largely generated for the disease modification sector to reduce the onset of symptoms from a disease-eliminating perspective.
•A limited number of available animal models for testing new Parkinson’s disease therapeutics limits the product pipeline for developing disease-eliminating drugs.
•Deep brain stimulation, a surgical procedure, is only conducted on patients suffering from severe Parkinson’s disease and patients with profound medication-induced side effects, such as debilitating dyskinesia.
•Boehringer Ingelheim, GlaxoSmilthKline (GSK), Orion Corporation, Merck & Co, UCB Pharma, and Novartis are some of the key big pharmaceutical competitors in this market.
Methodology and Scope
•This research service focusses on existing therapeutics and the product pipeline for the treatment of Parkinson’s disease using dopamine replacement therapies, dopamine agonists, Monoamine Oxidase (MAO) inhibitors, Catechol O-methyltransferase (COMT) inhibitors and other pharmacological approaches of current global interest. This research service does not cover vaccines.
•A product and pipeline assessment is provided for marketed and investigational products as well as combination regimens for Parkinson’s disease therapeutics. Segmentation by drug class is provided with supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources including the following: disease organisation web sites; public health organisation web sites; company publications, including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.
Parkinson’s disease is a chronic neurodegenerative disorder with a deceptive onset. The disease is characterised by the gradual loss of motor functions of the body due to the generation of dopamine-producing cells. Postural instability, freezing gait, and difficulty in speech and swallowing are some of the most commonly witnessed symptoms in an individual diagnosed with Parkinson’s disease.
The average incidence rate of the disease is between X and X per X people per year, as per World Health Organisation (WHO) data on Parkinson’s disease. No diagnosis for detecting the onset of the disease has been established yet. Parkinson’s disease commonly occurs to people over the age of X. Differences in the occurrence of the disease are based on environmental risk factors, and the genetic diversity of the global population, which is under the study. Caucasians in North America and Europe report a higher rate of disease prevalence in comparison to Asians in China and Japan. The lowest rate of the disease is recorded among the ethnic groups in Africa.
The disease progresses gradually, with deteriorating motor symptoms giving rise to motor fluctuations and dyskinesia.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
DelveInsight’s Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Schizophrenia for the seven majo ...
DelveInsight “Schizophrenia - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Schizophrenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). ...
DelveInsight “Parkinson's Disease - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Parkinson's Disease in seven major markets (US, France, Germany, Italy, Spain, ...